Skip to content

The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05908019
Acronym
PAH
Enrollment
100
Registered
2023-06-18
Start date
2023-05-05
Completion date
2024-12-31
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Web-based Health Care Program

Brief summary

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting…et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle. Therefore, it is important to assist patients to develop the ability of symptom management.

Interventions

OTHERWeb-based health care program

According to the participants' feedback and recommends, we will modify this program to make it more suitable. In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH.

Sponsors

National Defense Medical Center, Taiwan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. At least 20 years old, diagnosed by clinical specialists as patients with pulmonary hypertension (Group1 and Group 4) 2. Clear consciousness, able to communicate in Mandarin and Taiwanese, with normal hearing 3. Those who have internet or mobile internet at home 4. Adults without mental illness 5. No alcohol or drug abusers.

Exclusion criteria

1\. critical disease

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary Arterial Hypertension SymptomChange from Baseline pulmonary Arterial Hypertension Symptom at six monthsPulmonary Arterial Hypertension Symptom Interference Scale, PAHSS, The 10-point Likert scale higher scores mean a worse outcome.

Secondary

MeasureTime frameDescription
Social supportChange from Baseline social support at six monthsMultidimensional Scale of Perceived Social Support, (MSPSS). The 7-point Likert scale higher scores mean a better outcome.This instrument is 12 questions long and has been widely used and well validated.
Activity abilityChange from Baseline activity ability at six months6 Minute walk test, 6MWD
Pulmonary Hypertension Quality of lifeChange from Baseline quality of life at six monthsThe Cambridge Pulmonary Hypertension Outcome Review, (CAMPHOR). The 5-point Likert scale higher scores mean a better outcome.

Countries

Taiwan

Contacts

Primary ContactChen miao-yi, PhD Stusent
miaoyi820@gmail.com0955762820

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026